Controlling the complement system for prevention of red cell destruction

Current Opinion in Hematology

Volumn 12, Issue 2, 2005, Pages 117-122

  Yazdanbakhsh, Karina ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

Anti C5; Autoimmune hemolytic anemia; Complement; Complement inhibitors; Complement receptors; Paroxysmal nocturnal hemoglobinuria; Sickle cell disease; Transfusion reactions

Indexed keywords

COMPLEMENT INHIBITOR; NAFAMSTAT MESILATE;

AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TRANSFUSION REACTION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERYTHROCYTE; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; REVIEW;

ANEMIA, HEMOLYTIC; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; HEMOLYSIS; HUMANS;

EID: 14644390314     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000151712.53957.01     Document Type: Review

References (80)

1. Petz LD, Garratty G. Immune Hemolytic Anemias, edn 2. Philadelphia, PA: Churchill Livingston; 2004.
2. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990; 30:583-590.
3. Fischer JT, Petz LD, Garratty G, Cooper NR. Correlations between quantitative assay of red cell-bound C3, serologic reactions, and hemolytic anemia. Blood 1974; 44:359-373.
4. Taylor PR, Carugati A, Fadok VA, et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000; 192:359-366.
5. Carroll MC. The role of complement in B cell activation and tolerance. Adv Immunol 2000; 74:61-88.
6. Boackle SA, Holers VM, Chen X, et al. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 2001; 15:775-785.
7. Prodeus AP, Goerg S, Shen LM, et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998; 9:721-731.
8. Wu X, Jiang N, Deppong C, et al. A role for the Cr2 gene in modifying autoantibody production in systemic lupus erythematosus. J Immunol 2002; 169:1587-1592.
9. Hebbel RP. Beyond hemoglobin polymerization: the red blood cell membrane and sickle disease pathophysiology. Blood 1991; 77:214-237.
10. Tomasko MA, Chudwin DS. Complement activation in sickle cell disease: a liposome model. J Lab Clin Med 1988; 112:248-253.
11. Wang RH, Phillips G Jr, Medof ME, Mold C, Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest 1993; 92:1326-1335.
12. DeCeulaer K, Wilson WA, Morgan AG, Serjeant GR. Plasma haemoglobin and complement activation in sickle cell disease. J Clin Lab Immunol 1981; 6:57-60.
13. Wilson WA, Thomas EJ, Sissons JG. Complement activation in asymptomatic patients with sickle cell anaemia. Clin Exp Immunol 1979; 36:130-139.
14. Chudwin DS, Korenblit AD, Kingzette M, et al. Increased activation of the alternative complement pathway in sickle cell disease. Clin Immunol Immunopathol 1985; 37:93-97.
15. deCiutiis AC, Peterson CM, Polley MJ, Metakis LJ. Alternative pathway activation in sickle cell disease and beta-thalassemia major. J Natl Med Assoc 1978; 70:503-506.
16. Mold C, Tamerius JD, Phillips G Jr: Complement activation during painful crisis in sickle cell anemia. Clin Immunol Immunopathol 1995; 76:314-320.
17. Belcher JD, Marker PH, Weber JP, et al. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vasoocclusion. Blood 2000; 96:2451-2459.
18. Winkelstein JA, Drachman RH. Deficiency of pneumococcal serum opsonizing activity in sickle-cell disease. N Engl J Med 1968; 279:459-466.
19. Test ST, Woolworth VS. Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of membrane attack complex formation. Blood 1994; 83:842-852.
20. Stanley HA, Mayes JT, Cooper NR, Reese RT. Complement activation by the surface of Plasmodium falciparum infected erythrocytes. Mol Immunol 1984; 21:145-150.
21. Turrini F, Ginsburg H, Bussolino F, et al. Phagocytosis of Plasmodium falciparum-infected human red blood cells by human monocytes: involvement of immune and nonimmune determinants and dependence on parasite developmental stage. Blood 1992; 80:801-808.
22. Waitumbi JN, Opollo MO, Muga RO, et al. Red cell surface changes and erythrophagocytosis in children with severe Plasmodium falciparum anemia. Blood 2000; 95:1481-1486.
23. Giribaldi G, Ulliers D, Mannu F, et al. Growth of Plasmodium falciparum induces stage-dependent haemichrome formation, oxidative aggregation of band 3, membrane deposition of complement and antibodies, and phagocytosis of parasitized erythrocytes. Br J Haematol 2001; 113:492-499.
24. Wenisch C, Spitzauer S, Florris-Linau K, et al. Complement activation in severe Plasmodium falciparum malaria. Clin Immunol Immunopathol 1997; 85:166-171.
25. Goka BQ, Kwarko H, Kurtzhals JA, et al. Complement binding to erythrocytes is associated with macrophage activation and reduced haemoglobin in Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2001; 95:545-549.
26. Waitumbi JN, Donvito B, Kisserli A, et al. Age-related changes in red blood cell complement regulatory proteins and susceptibility to severe malaria. J Infect Dis 2004; 190:1183-1191.
27. Ham TH. Studies on destruction of red cell blood cells. I. Chronic hemolytic anemia with paroxysmal hemoglobinuria: an investigation of the mechanism of hemolysis, with observations on five cases. Arch Intern Med 1939; 64:1271.
28. Ham TH, Dingle JH. Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: certain immunological aspects of the hemolytic mechanism with special reference to serum complement. J Clin Invest 1939; 18:657-672.
29. Holguin MH, Fredrick LR, Bernshaw NJ, et al. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 1989; 84:7-17.
30. Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144:3478-3483.
31. Merry AH, Rawlinson VI, Uchikawa M, et al. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor). Br J Haematol 1989; 73:248-253.
32. Telen MJ, Green AM. The Inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood 1989; 74:437-441.
33. Yamashina M, Ueda E, Kinoshita T, et al. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1990; 323:1184-1189.
34. Motoyama N, Okada N, Yamashina M, Okada H. Paroxysmal nocturnal hemoglobinuria due to hereditary nucleotide deletion in the HRF20 (CD59) gene. Eur J Immunol 1992; 22:2669-2673.
35. Holguin MH, Martin CB, Bernshaw NJ, Parker CJ. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor. J Immunol 1992; 148:498-502.
36. Volanakis JE, Frank MM. The Human Complement System in Health and Disease. New York: Marcel Dekker, 1998.
37. Morgan BP, Harris CL. Complement therapeutics; history and current progress. Mol Immunol 2003; 40:159-170.
38. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359-395.
39. Potter PK, Cortes-Hernandez J, Quartier P, et al. Lupus-prone mice have an abnormal response to thioglycolate and an impaired clearance of apoptotic cells. J Immunol 2003; 170:3223-3232.
40. Davenport RD, Kunkel SL. Cytokine roles in hemolytic and nonhemolytic transfusion reactions [review]. Transfus Med Rev 1994; 8:157-168.
41. Sazama K. Transfusion errors: scope of the problem, consequences, and solutions. Curr Hematol Rep 2003; 2:518-521.
42. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardiai inflammation and necrosis. Science 1990; 249:146-151.
43. Lazar HL, Bokesch PM, van Lenta F, et al. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 2004; 110:11274-11279. In this randomized, placebo-controlled study that enrolled 564 high-risk patients undergoing cardiac surgery, sCR1 was shown to significantly decrease the incidence of mortality and myocardial infarction in male patients.
44. Zamora MR, Davis RD, Keshavjee SH, et al. Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. Chest 1999; 116:46S.
45. Zimmerman JL, Dellinger RP, Straube RC, Levin JL. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 2000; 28:3149-3154.
46. Yazdanbakhsh K, Kang S, Tamasauskas D, et al. Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy. Blood 2003; 101:5046-5052.
47. Mqadmi A, Abdullah Y, Yazdanbakhsh K. Characterization of complement receptor 1 domains for prevention of complement-mediated red cell destruction. Transfusion 2005 (in press).
48. Sahu A, Kay BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol 1996; 157:884-891.
49. Morikis D, Lambris JD. Structural aspects and design of low-molecular-mass complement inhibitors. Biochem Soc Trans 2002; 30:1026-1036.
50. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981; 661:342-345.
51. Inagi R, Miyata T, Maeda K, et al. FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a. Immunol Lett 1991; 27:49-52.
52. Miyata T, Fujita Y, Inagi R, et al. Effectiveness of nafamostat mesilate on glomerulonephritis in immune-complex diseases. Lancet 1993; 341:1353.
53. Fujita Y, Inoue I, Inagi R, et al. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia. Nippon Jinzo Gakkai Shi 1993; 35:393-397.
54. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-327.
55. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996; 33:1389-1401.
56. Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs 2002; 3:1017-1023.
57. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350:552-559. The prospect for use of a complement inhibitor for treatment of hemolytic diseases was demonstrated in this promising clinical study in which anti-C5 was administered to 11 patients with PNH and shown to reduce intravascular hemolysis, hemoglobinuria, and the need for transfusion.
58. Buerke M, Schwertz H, Seitz W, et al. Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits. J Immunol 2001; 167:5375-5380.
59. Roos A, Nauta AJ, Broers D, et al. Specific inhibition of the classical complement pathway by C1q-binding peptides. J Immunol 2001; 167:7052-7059.
60. Fung M, Loubser PG, Undar A, et al. Inhibition of complement, neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits. J Thorac Cardiovasc Surg 2001; 122:113-122.
61. Smith RA. Targeting anticomplement agents. Biochem Soc Trans 2002; 30:1037-1041.
62. Fraser DA, Harris CL, Smith RA, Morgan BP. Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeutic. Protein Sci 2002; 11:2512-2521.
63. Fraser DA, Harris CL, Williams AS, et al. Generation of a recombinant, membrane-targeted form of the complement regulator CD59: activity in vitro and in vivo. J Biol Chem 2003; 278:48921-48927.
64. Mossakowska D, Dodd I, Pindar W, Smith RA. Structure-activity relationships within the N-terminal short consensus repeats (SCR) of human CR1 (C3b/ C4b receptor, CD35): SCR 3 plays a critical role in inhibition of the classical and alternative pathways of complement activation. Eur J Immunol 1999; 29:1955-1965.
65. Miwa T, Zhou L, Hilliard B, et al. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Blood 2002; 99:3707-3716.
66. x moieties. J Immunol 1999; 162:4952-4959.
67. Rittershaus CW, Thomas LJ, Miller DP, et al. Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules. J Biol Chem 1999; 274:11237-11244.
68. Spitzer D, Unsinger J, Bessler M, Atkinson JP. ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol 2004; 40:911-919. Red blood cell-specific targeting of complement inhibitors was shown by this study's innovative approach of using antibody fragments with specificity to a highly expressed red cell protein.
69. Pickering MC, Botto M, Taylor PR, et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76:227-324.
70. Miyakawa Y, Yamada A, Kosaka K, et al. Defective immune-adherence (C3b) receptor on erythrocytes from patients with systemic lupus erythematosus. Lancet 1981; 2:493-497.
71. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004; 22:431-456.
72. Kemper C, Chan AC, Green JM, et al. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003; 421:388-392. In this exciting study, the complement regulatory protein CD46 was shown to be a costimulatory molecule for development of T-regulatory cells, providing a potential signaling target for generating such cells for prevention and treatment of autoimmune disease.
73. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002; 69:258-271.
74. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2001; 2:797-801.
75. Adams EM, Brown MC, Nunge M, et al. Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J Immunol 1991; 147:3005-3011.
76. Hall AM, Ward FJ, Vickers MA, et al. Interleukin-10-mediated regulatory T-cell responses to epitopes on a human red blood cell autoantigen. Blood 2002; 100:4529-4536.
77. Vigouroux S, Yvon E, Biagi E, Brenner MK. Antigen-induced regulatory T cells. Blood 2004; 104:26-33.
78. Carroll MC. CD21/CD35in B cell activation. Semin Immunol 1998; 10:279-286.
79. Bluestone JA, Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci U S A 2004; 101(suppl 2): 14622-14626.
80. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531-562.